cadonilizumab combined with neoadjuvant radiochemotherapy
TA2024-404-ESCC
Phase 2 other active
Quick answer
cadonilizumab combined with neoadjuvant radiochemotherapy for Esophageal Squamous Cell Carcinoma is a Phase 2 program (other) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Modality
- other
- Status
- active